Liver disease is a frequent complication in bone marrow transplant recipients and may occur early or late in the post-transplant period. Using ultrasound-guided fine needle (1.2 mm, 18 G) cutting biopsy, we studied six patients with undefined late post-BMT liver disease. No procedure-related complications occurred and all liver biopsies were informative, leading to changes in therapeutic approach. In our small series, the most frequent cause of hepatic damage was drug toxicity. US-guided fine needle cutting biopsy is a useful and easy tool for the work-up of unexplained post-BMT liver disease.
Liver disease occurs frequently after bone marrow transplantation (BMT) and has serious epidemiological and clinical implications. About one-half of patients who undergo allogeneic BMT develop hepatic complications, with an overall mortality rate due to liver failure of about 5%. 1 Liver damage may be due to acute or chronic graftversus-host disease (GVHD), veno-occlusive disease, viral, bacterial or mycotic infection, drug toxicity (cytotoxic or immunosuppressive drugs, antimicrobials, total parenteral nutrition), iron overload or the malignancy itself; 2-6 a combination of causes may occur simultaneously or sequentially in the same patient.
In our institution, the standard work-up for liver dysfunction occurring after BMT includes: history, physical examination, serum bilirubin and enzyme determination, search for viral markers (HBsAg, HBeAg, HBcAb, HBV-DNA; HCV-Ab and RNA; CMV-Ab and PP65 Ag; EBV-Ab; HSV-Ab; AdenoV-Ab) and for auto-antibodies (ANA, AMA, anti-LKM), iron status, complete coagulation studies and ultrasound (US) imaging. When the cause of liver damage cannot be determined via these non-invasive studies, we perform US-guided liver biopsy using a fine cutting needle with automatic aspiration. We report our recent experience in a small series of patients with post-BMT liver dysfunction.
Correspondence: B Rotoli, Divisione di Ematologia, Nuovo Policlinico, Via S Pansini 5, 80131, Naples, Italy Received 10 March 1998; accepted 7 May 1998
Materials and methods
From September 1997 to January 1998, six patients who had undergone BMT for hematological malignancies presented with liver dysfunction. Patient characteristics are shown in Table 1 . Except for patient No. 6, all patients had had normal liver function before BMT; liver dysfunction appeared from 3 to 8 months after BMT. Liver biopsy was performed after informed consent 1 to 8 months from the appearance of the hepatic disease. The procedure was performed in the day-hospital in five patients, while patient No. 1 needed hospitalization owing to severe hepatic disease. Platelet counts ranged from 50 to 100 × 10 9 /l and prothrombin times were normal in all patients. The procedure was carried out by two members of the hematological staff, using a portable Spazio-Hitachi (Tokyo, Japan) instrument with a 3.5 mHz probe connected to a puncture adaptor, and a 1.2 mm (18 G) diameter Menghini needle 150 mm in length with automatic aspiration (Biomol HS-Hospital, Rome, Italy). The US-guided biopsy was carried out from the left hepatic lobe; the cutting needle crossed hepatic tissue for at least 3 cm. After biopsy, patients remained in the supine position for 1 h with monitoring of vital signs every 15 min; then the abdominal US scan was repeated in order to look for procedure-related complications. All patients (except No. 1, who was an in-patient) left the hospital after 3 h and maintained telephone contact for 24 h. A repeat blood count was performed the next day. The histological sections were stained with hematoxylin and eosin, periodic acid Schiff reaction (with and without previous diastase digestion). A reticulin stain according to the method of Gomori, and a Perls stain were also carried out. HBsAg, HBcAg, HBV-DNA in situ hybridization were assessed, and CMV in the hepatocytes was also sought by immunohistochemistry. Immunohistochemistry was performed on the lymphocytes in inflammatory infiltrates. Histopathologic examination was performed in a single pathology unit (S Salvatore Hospital, Pesaro).
Results
All patients had excellent tolerance to the procedure; anesthesia was never used. No complications were observed during or after the biopsy. Vital sign monitoring was uneventful. The US scans repeated at 1 h showed no signs of bleeding or hematoma. Blood counts at 24 h showed no change. No platelet or red blood cell transfusions were needed before, during or after biopsies. A single attempt 6 Chronic active None Liver function hepatitis probably improvement due to recent reactivation of latent HBV infection achieved sufficient diagnostic tissue in all patients. Samples obtained measured about 1 mm in diameter and ranged in length from 25 to 40 mm. All liver biopsies were informative; histological findings for each patient are shown in Table 1 , and representative cases are shown in Figure 1 . In four cases the results of the histological examination led to treatment modification, which was followed by signs of improved liver function (Table 2) .
Discussion
Finding the exact cause of liver damage in BMT patients is pivotal to carrying out the proper treatment. Often standard non-invasive studies are insufficient to establish the cause of the disease; liver histology may suggest the correct diagnosis, avoiding unnecessary empirical and often injurious treatments. Obtaining hepatic tissue in BMT patients for histological assessment using Menghini, Tru-Cut or Jamshidi cutting needle (outer diameter from 1.8 to 2.0 mm) involves risk of bleeding and death. 7, 8 We used a smaller cutting needle (1.2 mm, 18 G) with automatic aspiration under direct US guidance for the study of late post-BMT liver dysfunction. The procedure was performed by hematologists trained in ultrasonography and in USguided needle biopsy. It was carried out in the day hospital, was well-tolerated, uncomplicated and informative in all cases. We suggest that this procedure be added to the standard work-up of otherwise unexplained post-BMT liver disease. Other more invasive and complex procedures used to obtain hepatic tissue, such as transjugular or laparoscopic liver biopsy, should be limited to patients with early post-BMT liver dysfunction and/or severe thrombocytopenia. 9, 10 Finally, it is interesting that in our small series the most frequent cause of hepatic damage was drug toxicity, often attributable to a cumulative effect.
